Cancer Immunology Community Seeks Better End Points
November 29, 2016
Drug developers are still hunting for surrogate end points that can better capture the benefits of checkpoint inhibitors, oncolytic viruses and modified T cell therapies.
Continue reading here.
Fresh treatments shift the focus from symptom management to repair.
Smart algorithms take aim at antimicrobial resistance.